A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®

Ki vehet részt

• Subjects who agree to participate in the study and sign the informed consent form
• Postmenopausal women who can walk freely, aged 50-85 years (including 50 and 85 years old)
• Subjects whose absolute value of bone mineral density (BMD) in the lumbar or total hip area meets T values ≤ -2.5 and > -4.0
• Subjects who must have at least one of the following risk factors: History of previous fragility fractures (occurring after the age of 40); history of hip fractures in fathers or mothers; increased bone turnover rate during screening; low body weight (BMI ≤ 19 kg/m2); advanced age (aged ≥ 65 years); current smoke
• The duration of spontaneous amenorrhea was >2 years or >2 years after bilateral oophorectomy. If the status of bilateral oophorectomy is unknown or if the ovaries are preserved after hysterectomy, follicle stimulating hormone (FSH) levels >40mIU/mL may be used to confirm the status of postoperative menopause

Ki nem vehet részt

• Oral or dental diseases: previous or current evidence of mandibular osteomyelitis or osteonecrosis; Acute dental or mandibular disease requiring oral surgery; Planning invasive dental surgery; Failure to recover from dental or oral surgery
• Previously used denosumab drugs
• Use of any of the following drugs within 6 weeks prior to screening that may affect bone metabolism
• Bone/metabolic disease
• Thyroid condition: Hyperthyroidism or hypothyroidism
• Malabsorption syndrome
• Renal disease - severe impairment of kidney function
• History of more than two vertebral fractures
• Malignant tumors
• Hyperparathyroidism or hypoparathyroidism
• Rheumatoid arthritis
• Vitamin D defViciency (25-hydroxyvitamin D, 25OHD <20 ng/mL)
• Use of intravenous bisphosphonates, fluoride, or strontium to treat osteoporosis within the last 5 years
• OOral bisphosphonates (used for at least 3 years, or used for less than 3 years but more than 3 months, with the last use occurring <1 year before the ICF)